Table 2 Treatment of each patient.

From: Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy

Patients

Response*

Chemotherapy regimen**

Radiation Dose

Patient 1

MPR

CBCDA + PTX+Durva

50 Gy/25 fr

Patient 2

SD

CBCDA + PTX+Durva

50 Gy/25 fr

Patient 3

CR

CBCDA + PTX+Durva

50 Gy/25 fr

Patient 7

MPR

CBCDA + PTX+Durva

50 Gy/25 fr

Patient 8

CR

CBCDA + PTX+Durva

50 Gy/2 5fr

Patient 11

SD

CDDP + PEM

45 Gy/25 fr

Patient 12

MPR

CDDP + VNR

45 Gy/25 fr

Resection alone

N.D.

N.D.

N.D.

  1. *MPR major pathological response, SD stable disease, CR complete response, PR partial response, **CBCDA carboplatin, PTX paclitaxel, Durva durvalumab, CDDP cisplatin, PEM pemetrexed, VNR vinorelbine. Durvalumab was concurrently administered with PTX, CBCDA and Radiotherapy.
Back to article page